ST葫芦娃 (605199)
Hainan Huluwa Pharmaceutical Group Co., Ltd.
K-Line Chart
No K-line data available
Company NameHainan Huluwa Pharmaceutical Group Co., Ltd.
Listing Date2020-07-10
Issue Price5.19RMB
Registered Capital40010.875210k RMB
Legal RepresentativeLiu Jingping
Registered AddressNo. 8, Yaogu Fourth Road, Phase II, Yaogu Industrial Park, Haikou National High-tech Industrial Development Zone, Haikou City, Hainan Province
IndustryTraditional Chinese Medicine II
Main BusinessEngaged in the research and development, production, and sales of traditional Chinese patent medicines and chemical drugs. The product application scope covers multiple therapeutic areas including respiratory system, digestive system, and systemic anti-infective.
Company ProfileThe Group is rooted in children's health, driven by innovative thinking and modern technology, absorbing the essence of traditional Chinese medicine. It integrates R&D, production, and sales to tailor-make pediatric drugs. It is a professional pediatric pharmaceutical group that has been selected as the Deputy Director Unit of the Pediatrics Branch of the Chinese Society of Traditional Chinese Medicine for two consecutive terms, and is a leading enterprise in China's pediatric respiratory treatment field. In 2017 and 2018, it was selected as a representative brand of Chinese pediatric medicine for the CCTV "Great Nation Brand" project for two consecutive years.
Based on its long-term development strategy, the Group has completed the construction of five intelligent manufacturing bases in Haikou, Hainan; Nanning, Guangxi; Laibin, Guangxi; and Chengde, Hebei. Meanwhile, the Group is planning the 200-mu Haikou "Huluwa Health Industrial Park." The implementation of this industrial park project will not only make the Group's industrial chain and corporate functions more complete but will also propel the Group to become a benchmark enterprise in the pediatric pharmaceutical field with the most comprehensive dosage forms, the largest production capacity, the highest technological content, and the strongest quality assurance capability in China.
Stock Details
1. Key Indicators
- Total Shares(W): 40010.88
- Circulating A-Shares(W): 40010.88
- Earnings Per Share(RMB): -0.0300
- Net Assets Per Share(RMB): 1.7228
- Operating Revenue(W RMB): 68271.99
- Total Profit(W RMB): -321.97
- **Net Profit Attributable to Parent(W RMB) **: -1121.39
- Net Profit Growth Rate(%): 90.46
- Weighted Return on Equity(%): -1.6100
- Operating Cash Flow Per Share(RMB): 0.1460
- Undistributed Profit Per Share(RMB): -0.1655
- Capital Reserve Per Share(RMB): 0.7262
2. Main Business
The main business covers:
- Research, development, production, and sales of proprietary Chinese medicines and chemical drugs.
3. Company Basic Information
- Company Name: Hainan Huluwa Pharmaceutical Group Co., Ltd.
- Listing Date: 2020-07-10
- Industry: Pharmaceuticals & Healthcare - Traditional Chinese Medicine
- Address: No. 8 Yaogu Fourth Road, Phase II, Yaogu Industrial Park, Haikou National High-tech Zone, Haikou City, Hainan Province, China
- Website: https://www.huluwayaoye.com/
- Company Profile: The company was established through the overall change of Huluwa Limited. Approved by the shareholders' meeting of Huluwa Limited and the company's founding meeting, it was converted into a joint stock company based on the audited net assets as of December 31, 2015, and completed industrial and commercial registration on March 8, 2016.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hainan Huluwa Investment Development Co., Ltd. | General Legal Person | 16707.90 | 41.76 |
| 2 | Zhejiang Fuwang Jude Health Development Co., Ltd. | General Legal Person | 5751.90 | 14.38 |
| 3 | Hangzhou Zhongjiarui Management Partnership (Limited Partnership) | General Legal Person | 2752.70 | 6.88 |
| 4 | ||||
| 5 | ||||
| 6 | ||||
| 7 | ||||
| 8 | ||||
| 9 | ||||
| 10 |
5. Concept Sectors
- ST Sector
- Hainan Free Trade Port
- Childcare Concept
- Generic Drugs
- Helicobacter Pylori
- Hepatitis Concept
- Innovative Drugs
- Yesterday Limit Up
- Specialized, Refined, Unique, and New (SRUN)
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information